Takeda Launches New Subsidiary in Israel

Zurich, Switzerland (ots/PRNewswire) -

Demonstrates Takeda's commitment to bring new, innovative
treatments to patients

Takeda Pharmaceuticals International GmbH ("Takeda") today
announced further expansion of its commercial platform with the
establishment of its wholly-owned subsidiary in Israel. Together with
Algeria, Ecuador, Peru, Singapore and Vietnam, Israel is the sixth
sales entity Takeda has opened this year to reinforce its platform in
growth markets.

Takeda Israel LTD will be headquartered in the Tel Aviv area and
will be responsible for the sales and marketing of selected products
from Takeda's portfolio and pipeline, with an initial focus on
oncology. Takeda Israel will also seek local partners with
complementary portfolios, through which to launch additional proven
medicines from its current portfolio. Through its established network
of local partners, Takeda products currently sold in Israel are
Actos(R) (pioglitazone), Atacand(R) (candesartan), Contoloc(R)
(pantoprazole), Lucrin(R) (leuroprelin), Xefo(R) (lornoxicam),
Mepact(R) (mifamurtide) and other treatments in various therapeutic
areas.

Israel is a highly developed pharma market with a universal
healthcare system that values innovative medicines. The National
Health Insurance constantly expands its list of reimbursable
products, having dedicated more than a third of its additional funds
over the last ten years to cancer treatment*. According to Business
Monitor International, pharmaceutical sales in Israel totaled US$ 1.5
billion in 2012 and are expected to grow at a compound annual rate of
6%* between 2013 and 2017, driven by population growth and an
increased need for specialty treatments. Takeda plans to outgrow the
market over the same period.

Arie Kramer has been appointed Country Manager for Israel. He
joins from AbbVie Biopharma, where he headed Finance and Strategic
Commercial Planning. Previously he had served as General Manager,
Chief Financial Officer and Operations Manager at Novartis Consumer
Health in Israel.

"There is a growing demand for specialty treatments in Israel,"
said Arie Kramer, Country manager Takeda Israel. "The establishment
of our subsidiary demonstrates our commitment to bringing innovative
new medicines to patients and will enable us to address some of the
country's current unmet healthcare needs."

Patients are at the center of Takeda's approach to R&D and the
Company has one of the richest and deepest pipelines in the industry
today.

Takeda is a global pharmaceutical company based in Japan that is
poised to meet the challenges of the constantly evolving
pharmaceutical market. For more than 230 years, Takeda has been
committed to serving the global community through healthcare
solutions from prevention to care to cure. Takeda is the largest
pharmaceutical company in Japan and the 15th largest in the world,
with approximately 30,000 employees in 70 countries. The Company's
mission is to strive toward better health for people worldwide
through leading innovation in medicine.

[*]Data Source: Data on file - Ministry of Health approved
technologies list for National Health Basket - 2012

About Takeda Pharmaceuticals International GmbH

Headquartered in Zurich as a wholly owned subsidiary of Takeda
Pharmaceutical Company Limited, Osaka, Japan, the company has a
commercial presence covering more than 70 countries, with particular
strength in Asia, North America, Europe and fast-growing emerging
markets including Latin America, Russia-CIS and China. Takeda is
ranked 15th by global Rx sales, 14th in the BRIC countries and 18th
in Europe Areas of focus include cardiovascular and metabolic,
oncology, respiratory and immunology, central nervous system, general
medicine, and vaccines.

Takeda is a research-based global company with its main focus on
pharmaceuticals. As the largest pharmaceutical company in Japan and
one of the global leaders of the industry, Takeda is committed to
strive towards better health for people worldwide through leading
innovation in medicine. Through the integration of Millennium
Pharmaceuticals and Nycomed, Takeda has been transforming itself,
broadening its therapeutic expertise and geographic outreach.

Additional information about Takeda is available through its
corporate website, http://www.takeda.com.

This press release has been issued by Takeda Pharmaceuticals
International GmbH, Thurgauerstrasse 130, CH-8152 Glattpark-Opfikon,
Zurich, Switzerland.

ots Originaltext: Takeda Pharmaceuticals Europe Ltd
Im Internet recherchierbar: http://www.presseportal.de

Contact:
International Contact: Takeda Pharmaceuticals International GmbH
Birgit Gronkowski, +41-44-555-1506, Birgit.Grokowski@takeda.com.
Local
contact: Goldfinger Communications, Mahogany Levy, +972-526155308,
Mahogany@goldfingercom.com.